Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116467 · ClinicalTrials.gov registry record · Phase 2
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
A Phase 2 study, sponsored by Cell Genesys.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00116467: Completed Phase 2 study, sponsored by Cell Genesys.
NCT00116467 is a Phase 2 study that has completed, run by Cell Genesys. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116467, a Phase 2 study, has completed, sponsored by Cell Genesys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
Interventions
- BIOLOGICAL GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2001-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116467
The ClinicalTrials.gov registry entry for NCT00116467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cell Genesys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing) is the first listed.
NCT00116467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116467 about?
NCT00116467 is a clinical study titled "Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia". The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
What is the current status of trial NCT00116467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2001-03. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00116467?
The interventions under investigation include: GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00116467?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.